Alpha 2.0
Login Register
» Authors » Stephane St-Onge

Stephane St-Onge

Explore the profile of Stephane St-Onge including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 214
Followers 0
Related Specialties
Biochemistry
Biology
Neurology
Top 10 Co-Authors
Christopher Walpole
Madeleine Heroux
Michel Bouvier
William Brown
Hua Yang
Marilyn Carrier
Ellen K Kick
Dominic Salois
Gayani Fernando
Etienne Lessard
Published In
Bioorg Med Chem Lett
JACC Basic Transl Sci
ACS Pharmacol Transl Sci
Pain
Circ Heart Fail
Affiliations
Soon will be listed here.
Recent Articles
1.
Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure-Function Post Myocardial Infarction
Lupisella J, St-Onge S, Carrier M, Cook E, Wang T, Sum C, et al.
ACS Pharmacol Transl Sci . 2022 Oct; 5(10):892-906. PMID: 36268126
Formyl peptide receptor 2 (FPR2) plays an integral role in the transition of macrophages from a pro-inflammatory program to one that is pro-resolving. FPR2-mediated stimulation of resolution post myocardial infarction...
2.
Effector membrane translocation biosensors reveal G protein and βarrestin coupling profiles of 100 therapeutically relevant GPCRs
Avet C, Mancini A, Breton B, Le Gouill C, Hauser A, Normand C, et al.
Elife . 2022 Mar; 11. PMID: 35302493
The recognition that individual GPCRs can activate multiple signaling pathways has raised the possibility of developing drugs selectively targeting therapeutically relevant ones. This requires tools to determine which G proteins...
3.
Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction
Garcia R, Lupisella J, Ito B, Hsu M, Fernando G, Carson N, et al.
JACC Basic Transl Sci . 2021 Sep; 6(8):676-689. PMID: 34466754
Dysregulated inflammation following myocardial infarction (MI) leads to maladaptive healing and remodeling. The study characterized and evaluated a selective formyl peptide receptor 2 (FPR2) agonist BMS-986235 in cellular assays and...
4.
In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure
Gargalovic P, Wong P, Onorato J, Finlay H, Wang T, Yan M, et al.
Circ Heart Fail . 2021 Mar; 14(3):e007351. PMID: 33663236
Background: New heart failure therapies that safely augment cardiac contractility and output are needed. Previous apelin peptide studies have highlighted the potential for APJ (apelin receptor) agonism to enhance cardiac...
5.
Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment
Garcia R, Ito B, Lupisella J, Carson N, Hsu M, Fernando G, et al.
JACC Basic Transl Sci . 2020 Jan; 4(8):905-920. PMID: 31909300
Dysregulated inflammation following myocardial infarction (MI) promotes left ventricular (LV) remodeling and loss of function. Targeting inflammation resolution by activating formyl peptide receptors (FPRs) may limit adverse remodeling and progression...
6.
Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease
Plowright A, Nilsson K, Antonsson M, Amin K, Broddefalk J, Jensen J, et al.
J Med Chem . 2012 Dec; 56(1):220-40. PMID: 23227781
Agonists of the cannabinoid receptor 1 (CB1) have been suggested as possible treatments for a range of medical disorders including gastroesophageal reflux disease (GERD). While centrally acting cannabinoid agonists are...
7.
N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration
Wei Z, Yang H, Liu Z, Tremblay M, Johnstone S, Beha S, et al.
Bioorg Med Chem Lett . 2012 May; 22(12):3884-9. PMID: 22607668
Cannabinoid CB(1) receptor agonists exhibit potent analgesic effects in rodents and humans, but their clinical utility as analgesic drugs is often limited by centrally mediated side effects. We report herein...
8.
γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration
Cheng Y, Pourashraf M, Luo X, Srivastava S, Walpole C, Salois D, et al.
Bioorg Med Chem Lett . 2012 Jan; 22(4):1619-24. PMID: 22284817
An oral, peripherally restricted CB1/CB2 agonist could provide an interesting approach to treat chronic pain by harnessing the analgesic properties of cannabinoids but without the well-known central side effects. γ-Carbolines...
9.
A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain
Yu X, Cao C, Martino G, Puma C, Morinville A, St-Onge S, et al.
Pain . 2010 Aug; 151(2):337-344. PMID: 20696525
Cannabinoids are analgesic in man, but their use is limited by their psychoactive properties. One way to avoid cannabinoid receptor subtype 1 (CB1R)-mediated central side-effects is to develop CB1R agonists...
10.
N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: the development of diaryl amino piperidines as potent delta opioid receptor agonists with in vivo anti-nociceptive activity in rodent models
Jones P, Griffin A, Gawell L, Lavoie R, Delorme D, Roberts E, et al.
Bioorg Med Chem Lett . 2009 Oct; 19(21):5994-8. PMID: 19800791
We have investigated a series of phenolic diaryl amino piperidine delta opioid receptor agonists, establishing the importance of the phenol functional group and substitution on the piperdine nitrogen for delta...